Safety and effectiveness of the Genous™ endothelial progenitor cell-capture stent in the first year following ST-elevation acute myocardial infarction: A single center experience and review of the literature.
OBJECTIVE
The Genous™ stent (GS) is designed to accelerate endothelization, which is potentially useful in the pro-thrombotic environment of ST-elevation acute myocardial infarction (STEMI). We aimed to evaluate the safety and effectiveness of the GS in the first year following primary percutaneous coronary intervention (PCI) and to compare our results with the few previously published studies.


METHODS
All patients admitted to a single center due to STEMI that underwent primary PCI using exclusively GS, between May 2006 and January 2012, were enrolled. The primary study endpoints were major adverse cardiac events (MACEs), defined as the composite of cardiac death, acute myocardial infarction and target vessel revascularization, at one and 12 months.


RESULTS
In the cohort of 109 patients (73.4% male, 59 ± 12 years), 24.8% were diabetic. PCI was performed in 116 lesions with angiographic success in 99.1%, using 148 GS with median diameter of 3.00 mm (2.50-4.00) and median length of 15 mm (9-33). Cumulative MACEs were 2.8% at one month and 6.4% at 12 months. Three stent thromboses (2.8%), all subacute, and one stent restenosis (0.9%) occurred. These accounted for the four target vessel revascularizations (3.7%). At 12 months, 33.9% of patients were not on dual antiplatelet therapy.


CONCLUSIONS
GS was safe and effective in the first year following primary PCI in STEMI, with an apparently safer profile comparing with the previously published data.


CONCLUSIONS
We report the safety and effectiveness of the Genous™ stent (GS) in the first year following primary percutaneous coronary intervention in ST-elevation acute myocardial infarction. A comprehensive review of the few studies that have been published on this subject was included and some suggest a less safe profile of the GS. Our results and the critical review included may add information and reinforce the safety and effectiveness of the GS in ST-elevation in acute myocardial infarction.
Cardiology Department, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. Electronic address: tiagopsilva@sapo.pt.
Tiago
T
Pereira-da-Silva
Luís
L
Bernardes
Duarte
D
Cacela
António
A
Fiarresga
Lídia
L
Sousa
Lino
L
Patrício
Rui Cruz
RC
Ferreira
D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D017023:Coronary Angiography / Q000379:methods; D004562:Electrocardiography / Q000379:methods; D042783:Endothelial Cells / Q000166:cytology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery*; D012196:Review Literature as Topic; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000601:surgery*; D016896:Treatment Outcome
DAPT; Endothelial progenitor cell; GS; Genous™ stent; MACE; PCI; Percutaneous coronary intervention; ST-elevation acute myocardial infarction; STEMI; Stent; TIMI; TLR; TVR; dual antiplatelet therapy; major adverse cardiac event; percutaneous coronary intervention; target lesion revascularization; target vessel revascularization; thrombolysis in myocardial infarction